Table 3 Clinical evaluation of SOX14 methylation in each of the differentiated groups
From: SOX14 hypermethylation as a tumour biomarker in cervical cancer
Groups | AUC | Cut off | Sen (%) | Spe (%) | YI |
|---|---|---|---|---|---|
Normal vs. Cancer | 0.99 | 87.21 | 94.12 | 96.30 | 0.90 |
Precancer (Normal+CINII+CINIII) vs. Cancer | 0.94 | 128.45 | 94.12 | 86.46 | 0.81 |
Normal vs. ≥ CINII | 0.81 | 10.37 | 74.42 | 81.48 | 0.56 |